12:00 AM
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

K101: Phase III data

In a double-blind, European Phase III trial, once-daily topical K101 met the primary endpoint of a significant improvement in mycological cure rate vs. placebo after 6 months in 395 patients...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >